No CrossRef data available.
Article contents
Receptores IL-6 solubles en el suero y el líquido cefalorraquídeo de pacientes esquizofrénicos paranoides
Published online by Cambridge University Press: 12 May 2020
Resumen
Los niveles del receptor interleucina-6 soluble (sIL-6R) están íntimamente relacionados con los niveles de interleucina-6 (IL-6), y los sIL-6R aumentan las propiedades activadoras inmunes de la IL-6. Estimamos los niveles de sIL-6R en el suero en 25 pacientes esquizofrénicos y 25 controles sanos. En los pacientes, se midieron también los niveles de sIL-6R en el LCR. Las manifestaciones psicopatológicas se evaluaron según el sistema AMDP. Encontramos una correlación significativa entre los niveles del sIL-6R en el suero y en el LCR, lo que indica que los niveles en el suero pueden ser un marcador significativo para la acción central del sIL-6R. Además, se observaron correlaciones significativas entre el síndrome paranoide-alucinatorio y los niveles de sIL-6R tanto en el suero como en el LCR. Este resultado indica que la IL-6 desempeña un papel en los síntomas paranoides-alucinatorios en la esquizofrenia. Es posible entender esto en relación con la influencia de la IL-6 en la neurotransmisión catecolaminérgica. Los efectos reguladores por disminución del tratamiento neuroléptico sobre el sIL-6R demuestran que los niveles de sIL-6R disminuyen en el grupo entero de pacientes esquizofrénicos en comparación con los controles.
- Type
- Artículo original
- Information
- Copyright
- Copyright © European Psychiatric Association 1998
References
Bibliografía
Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie. Das AMDP System. Berlin: Springer, 1979.Google Scholar
Banks, WAKastin, AJGutiérrez, EG.Penetration of interleukin-6 across the murine blood-brain barrier. Neurosci Lett 1994; 179: 53-6.CrossRefGoogle ScholarPubMed
Bauer, KKornhuber, JBlood-cerebrospinal fluir barrier in schizophrenic patients. Eur Arch Psychiatr Neurol Sci 1987; 236: 257-9.CrossRefGoogle Scholar
Borbon, DBaumann, UAngst, JHelmchen, HHippius, H eds. AMDP System in Pharmacopsychiatry. Basel: Karger, 1983.Google Scholar
De Vries, HE Blom-Rosemalen MCM, van Oosten, Mde Boer, AGvan Berkel, TJC, Breimer, DDet al.The influence of cytokines to the integrity of the blood brain barrier in vitro. J Neuroimmunol 1996; 64: 37-43.CrossRefGoogle ScholarPubMed
Dunn, AJEndotoxin-induced activation of cerebral catecholamine and serotonin metabolism: comparison with interleukin-1. J Pharmacol Exp Ther 1992; 261: 96-49.Google ScholarPubMed
Frei, KMalipiero, UVLeist, TPZinkermagel, RMSchwab, MEFontana, AOn the cellular source and function of interleukin-6 produced in the central nervous system in viral diseases. Eur J lmmunol 1989; 19: 689-94.CrossRefGoogle ScholarPubMed
Galinowski, ABarbouche, RTruffinet, PLouzir, HPoirier, MFBouvet, Oet al.Natural autoantibodies in schizophrenia. Acta Psychiatr Scand 1992; 85: 240-2.CrossRefGoogle Scholar
Ganguli, RRabin, BSKelly, RH.Multiple autoantibodies and autoimmune disease in schizophrenic patients: evidence for an autoimmune pathogenesis. In: Hadden, JWMasek, KNistico, G eds. Interactions Among Central Nervous System, Neuroendocrine and Imniune Systems. Rome-Milan: Pythagora Press, 1989: 364-85.Google Scholar
Ganguli, RYang, ZShurin, GChengappa, RBrar, JSGubbi, AVet al.Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 1994; 51: 1-10.Google ScholarPubMed
Gebhardt, RPietzcker, AStrauss, AStoeckl, MLanger, CFreudenthal, KScale building in the AMDP System. Arch Psychiatr Neurol Sci 1983; 233: 223-45.Google Scholar
Groβkopf, AMüller, NMalo, AWank, R. HLA-DR and DQ alieles in schizophrenics and manic depressive disorders: potential role for the narcolepsy and multiple sclerosis associated allele DQB 1*0602 in schizophrenia subytpes. Schizophr Res 1996; (in press).Google Scholar
Hama, TKushima, YMiyamoto, MKubota, MTakei, NHatanaka, HInterleukin-6 improves the survival of mesencephalic catochelaminergic and septal cholinergic neurons from patnatal, two-week-old rats in cultures. Neuroscience 1991; 40: 445-52.CrossRefGoogle ScholarPubMed
Hornberg, MArolt, VWilke, IKruse, AKirchner, HProduction of interferons and lymphokines in leukocyte cultures of patients with schizophrenia. Schizophr Res 1995; 15: 237-42.CrossRefGoogle ScholarPubMed
Kirch, DGKaufman, CAPapadopoulos, NMMartin, BWeinberger, DRAbnormal cerebrospinal fluid protein indices in schizophrenia. Biol Psychiatry 1985; 20: 1039-46.CrossRefGoogle Scholar
Licinio, JSeibyl, JPAltemus, MCharney, DSKrystal, JHElevated levels of interleukin-2 in neuroleptic-free schizophrenics. Am J Psychiatry 1993; 150: 1408-10.Google Scholar
Mackiewicz, ASchooltink, HHeinrich, PCRose-John, S.Complex of soluble human IL-6-receptor/IL-6 upregulates expression of acute-phase proteins. J lmmunol 1992; 49: 2021-7.Google Scholar
Maes, MEvidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 11-38.CrossRefGoogle ScholarPubMed
Maes, MMeltzer, HYScharpe, SBosmans, ESuy, EDe Meester, Iet al.Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatric Res 1993a; 49: 11-27.Google ScholarPubMed
Maes, M Scharpé S, Meltzer, HYBosmans, ESuy, ECalabrese, Jet al.Relationships between lower plasma. L-Tryptophan levels and immune-inflammatory variables in depression. Psychiatry Res 1993b; 49: 151-65.CrossRefGoogle ScholarPubMed
Maes, MMeltzer, HYBosmans, EImmune-inflammatory markers in schizophrenics: comparison to normal Controls and effects of clozapine. Acta Psychiatr Scand 1994; 89: 346-51.CrossRefGoogle Scholar
Maes, MBosmans, EMeltzer, HY.Immunoendocrine aspects of major depression. Relationships between plasma interleukin-6 and soluble interleukin-2 receptor, prolactin and cortisol. Eur Arch Psychiatr Clin Neurosci 1995a; 245: 172-8.Google ScholarPubMed
Maes, MBosmans, ECalabrese, JSmith, RMeltzer, HY.Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 1995b; 29: 141-52.Google ScholarPubMed
McAllister, CG van Kammen, DPRehn, TJMiller, ANGurklis, JKelley ME et al.Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry 1995; 152: 1291-7.Google ScholarPubMed
Müller, N.The role of the cytokine-network in the CNS, and psychiatric disorders. Nervenarzt 1997; 68: 11-20.Google ScholarPubMed
Müller, NAckenheil, M.The immune system and schizophrenia: In: Leonard, BMiller, K eds. Stress, 1inmune System and Psychiatry. Chichester, New York: Wiley & Sons, 1995a: 137-64.Google Scholar
Müller, NAckenheil, M.Immunoglobulin and albumin contents of cerebrospinal fluid in schizophrenic patients: the relationship to negative symptomatology. Schizophr Res 1995b; 14: 223-8.Google ScholarPubMed
Müller, NAckenheil, MHofschuster, EMempel, WEckstein, RCellular immunity in shizophrenic patients before and during neuroleptic therapy. Psychiatry Res 1991; 37: 147-60.Google Scholar
Müller, NAkenheil, MHofschuster, EMempel, WEckstein, RInvestigation of the cellular immunity during depression and the free interval: evidence for an immune activation in affective psychosis. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17: 713-30.CrossRefGoogle Scholar
üller, NEmpl, MPutz, ASchwarz, MAckenheil, MImmunological effects of treatment in schizophrenia. Adv Biol Psychiatry 1997; 18: 78-84.Google Scholar
Muraguchi, AHirano, TTang, BMatsuda, THorii, YNakajima, Ket al.The essential role of B-cell stimulating factor 2 (BSF-2/II6) for the terminal differentiation of the B-cells. J Exp Med 1988; 167; 332-44.CrossRefGoogle Scholar
Plata-Salaman, CR.Immunoregulators in the nervous System. Neurosci Behav Rev 1991; 15: 185-215.CrossRefGoogle ScholarPubMed
Saija, APrinci, PLanza, MScalese, MAramnejad, EDe Sarro, A.Systemic cytokine administration can affect blood-brain barrier permeability in the rat. Life Sci 1995; 56: 775-84.CrossRefGoogle ScholarPubMed
Sawada, MSuzumura, AMarunouchi, TTNF-a induces IL-6 production by astrocytes, but not by microglia. Brain Res 1992; 583: 296-9.CrossRefGoogle Scholar
Schöbitz, BPezeshki, GPohl, THermann, UHeinrich, PCHolsboer, Fet al.Soluble interleukin-6 (IL-6) receptor augments central effects of IL-6 in vivo. FASEB J 1995; 9: 659-64.Google Scholar
Seiler, WMüller, HHiemke, C.Diurnal variations of plasma interleukin-6 in man: methodological implications of continuous use of indwelling cannulae, An NY AcadSci 1995; 762: 468-70.CrossRefGoogle ScholarPubMed
Smith, RSA comprehensive macrophage-T-lymphocyte theory of schizophrenia. Med Hypotheses 1992; 39: 248-57.CrossRefGoogle ScholarPubMed
Song, CLeonard, BEAn acute phase protein response in the olfactory bulbectomised rat: effect of sertraline treatment. Med Sci Res 1994; 22: 313-4.Google Scholar
Zalcman, S Green-Johnson, JMMurray, LNance, DMDyck, DAnisman, Het al.Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res 1994; 643: 40-9.CrossRefGoogle ScholarPubMed